17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN HCL

17-DMAG (150270-08-9) is an analog of geldanamycin (Cat.# 10-1084) that displays superior pharmacological properties. 17-DMAG inhibits HSP90 and induces apoptosis in a variety of tumor cell lines. Inhibits angiogenesis. Cell Permeable.

17-Dimethylaminogeldanamycin is a metabolite/analog of geldanamycin(G304500). Geldanamycin is a potent antitumor antibiotic active at nanomolar concentration against 60 cell lines.It binds specifically to the heat shock protein Hsp90 and to its endoplasmic reticulum homologue GP96, and thus interferes with conformational maturation of proteins and the cellular stress response. In addition, it is a potent inhibitor of the nuclear hormone receptor family.

ChEBI: Alvespimycin is a 19-membered macrocyle that is geldanamycin in which the methoxy group attached to the benzoquinone moiety has been replaced by a 2-(N,N-dimethylamino)ethylamino group. It has a role as a Hsp90 inhibitor. It is a secondary amino compound, a tertiary amino compound, an ansamycin, a member of 1,4-benzoquinones and a carbamate ester. It is functionally related to a geldanamycin.

[1] ELIZABETH R GLAZE. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.[J]. Cancer Chemotherapy and Pharmacology, 2005, 56 6: 637-647. DOI:10.1007/s00280-005-1000-9
[2] GURMEET KAUR. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.[J]. Clinical Cancer Research, 2004, 10 14: 4813-4821. DOI:10.1158/1078-0432.ccr-03-0795